Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147642 | 1.00 | TSHR (0.40) | TSHRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL10146918 | 0.86 | TSHR (0.57) | TSHRKDM4EALDH1A1HPGD | |
| SCHEMBL20061337 | 0.86 | MEN1 (0.41) | TSHRKDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL20061339 | 0.86 | KDM4E (0.40) | KDM4EALDH1A1HPGDMEN1THRB | |
| SCHEMBL28913545 | 0.81 | LIPG (0.36) | KDM4EALDH1A1HPGDMEN1THRB | |
| SCHEMBL28913544 | 0.81 | LIPG (0.36) | KDM4EALDH1A1HPGDMEN1THRB | |
| SCHEMBL1694904 | 0.81 | MEN1 (0.40) | HPGDGAAMEN1KMT2ACTSS | |
| SCHEMBL1695324 | 0.81 | MEN1 (0.40) | HPGDGAAMEN1KMT2ACTSS | |
| SCHEMBL10146874 | 0.79 | MAPT (0.39) | TSHRALDH1A1HPGDKMT2ACTSS | |
| SCHEMBL1694878 | 0.79 | MAPT (0.39) | TSHRALDH1A1HPGDKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | TSHR 1224/4885KDM4E 1440/4885ALDH1A1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.